Early Detection of Skin Tumors Using a Telemedicine Tool in Primary Care

Condition(s) studied

Investigational drug(s) / intervention(s)

Intervention with telemedicine tool: The diagnostic management of enrolled patients will be guided by standardized procedures carried out in general practitioners' offices. Physicians will be trained to identify suspicious skin lesions, capture high-resolution images using dermatoscopes, and transfer the data into advanced telemedicine software. The platform, supported by AI-driven algorithms, enables precise risk stratification of lesions and facilitates remote consultation with collaborating dermatologists. Patients with high-risk lesions will be referred to specialized dermatology centers for further examination and intervention. In cases where excision of a lesion is performed, histopathological assessment will be conducted, and results will be systematically recorded within the dedicated telemedicine platform, ensuring secure and efficient information exchange between dermatologists and general practitioners.

Study summary

The project is a national, prospective, multicenter, single-arm interventional pilot of screening skin tumors in the Czech Republic.

The primary aim of the project is to methodically prepare, implement and evaluate a pilot project that will verify the suitability of the proposed procedure of early detection of skin tumors by using a telemedicine tools and setting up and testing new methods and implementation into the system of social health care.

Eligibility

Primary outcome measure(s)

• Potential malignancies — From enrollment to the end of examination - baseline.
  Proportion of individuals with a potential presence of malignancy (detected through the telemedicine tool).
• Confirmed malignancies — From enrollment to the end of diagnosis at 3 months.
  Proportion of individuals with confirmed potential malignancy by a dermatologist.
• Confirmed malignancies by histology — From enrollment to the end of diagnosis at 6 months.
  Proportion of individuals in whom the diagnosis of malignancy was confirmed histologically.

Trial sites (5)

More Institute of Health Information and Statistics of the Czech Republic trials in Czechia